Merck KGaA Joins Race To Develop Next-Gen PARP Inhibitors
Links Up With Italy’s Nerviano
PARP inhibitors have had great success in treating a number of cancers but the German major has placed a $65m bet that Nerviano's selective PARP1 approach could produce a safer and more efficacious option.
